Surrozen, Inc./DE (SRZN) · Oct 20, 2026 · Share issuance
$95.1M financing — ~$95.1M gross proceeds; expected runway into 2029
Surrozen closes its $95.1M financing tranche after FDA clearance, extending runway into 2029 while adding substantial share and warrant dilution.
Surrozen is an early-stage ophthalmology biotech moving SZN-8141 into its first clinical study for diabetic macular edema while preparing SZN-8143 for development; the FDA cleared the SZN-8141 IND on October 2, 2026, and the company had already targeted DUET initiation by year-end 2026.
The financing removes the near-term funding overhang. Surrozen closed the second and final tranche of its March 2025 private placement for approximately $95.1 million in gross proceeds, after the FDA milestone triggered the closing.
| Item | Filing figure |
|---|---|
| Gross proceeds | ~$95.1 million (Financing announcement) |
| Expected cash runway | Into 2029 (Financing announcement) |
| Common shares issued | ~5.7 million (Financing announcement) |
| Pre-funded warrant shares | ~2.5 million (Financing announcement) |
| Series E warrant shares | ~4.1 million (Financing announcement) |
| Series E warrant exercise price | $11.54 per share (Financing announcement) |
| First DUET patient dosing | Fourth quarter 2026 (DUET program update) |
| Initial DUET data | Second half of 2027 (DUET program update) |
The cash meaningfully advances the pipeline, but this is not a surprise financing. The second tranche was negotiated in March 2025 and explicitly tied to FDA clearance of SZN-8141, so the direction of the event was already known; the new information is the completed funding and the company’s stated runway into 2029. That should allow completion of the DUET Phase 1b/2a study and initial Phase 1b work on SZN-8143 without an immediate financing requirement.
The cost is substantial future dilution. The company added roughly 5.7 million shares plus securities convertible into millions more shares, taking the reported common stock count to approximately 17.8 million before considering the additional pre-funded warrants and outstanding warrants. 〔0〕 The financing also requires a resale registration statement within 30 calendar days, which could increase the visible supply of tradable securities.
The real test now shifts from financing to clinical execution. Surrozen expects first patient dosing in DUET during the fourth quarter of 2026 and initial data in the second half of 2027; the financing buys time to reach those milestones, but it does not validate efficacy or establish that the cash runway will be sufficient if trials expand or costs rise. 〔1〕
Bottom line: This completes the expected milestone-linked financing and materially strengthens Surrozen’s ability to run its ophthalmology programs through early clinical readouts. It advances the business, but the benefit is balanced by meaningful dilution and was partly anticipated once the IND cleared.
First DUET patient dosing, fourth quarter 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!